middle.news
Chimeric Therapeutics Engages Adviser for Strategic Review to Unlock Hidden Value
9:01am on Wednesday 1st of July, 2026 AEST
•
Healthcare
Read Story
Chimeric Therapeutics Engages Adviser for Strategic Review to Unlock Hidden Value
9:01am on Wednesday 1st of July, 2026 AEST
Key Points
Hawkesbury Partners appointed as independent financial adviser
Review to explore partnerships, licensing, mergers, and capital options
Company invested over A$80 million in clinical and manufacturing infrastructure
No guarantee of transaction outcome from the review
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE